Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELOA pseudogene 1 (ELOAP1) is a human pseudogene that is homologous to the elongin A gene (also known as transcription elongation factor B subunit 3, TCEB3), but it does not encode a functional protein[2][5]. Pseudogenes are generally classified as unitary, unprocessed (duplicated), or processed; they often arise from gene duplication or retrotransposition events and accumulate mutations that render them nonfunctional at the protein level. Some pseudogenes, through their RNA transcripts, may regulate cellular processes by acting as decoys for microRNAs or participating in gene expression regulation, but there is no current evidence that ELOAP1 performs such regulatory functions. Because ELOAP1 does not produce a functional protein, it is not considered a direct molecular target for drugs or therapeutic intervention[2][5]. Key distinction: Do not confuse ELOAP1 with ELOA (elongin A), the functional protein-coding gene that forms part of the transcription elongation factor B complex and has recognized roles in transcription regulation and disease, particularly tumorigenesis[1][3]. ELOAP1 specifically refers to a non-protein-coding, non-functional pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ELOA pseudogene 1 (ELOAP1).